Atypical neuroleptics as a treatment of agitation and anxiety in Alzheimer's disease: Risks or benefits

Expert Review of Neurotherapeutics

Volumn 6, Issue 5, 2006, Pages 705-710

  Moretti, Rita ^a   Torre, Paola ^a   Antonello, Rodolfo M ^a   Pizzolato, Gilberto ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Atypical neuroleptics; Behavioral disorders; Cerebrovascular side effects; Dementia

Indexed keywords

CLOZAPINE; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; NEUROLEPTIC AGENT;

AGITATION; AKATHISIA; ALZHEIMER DISEASE; ANXIETY; BEHAVIOR DISORDER; CAREGIVER; COGNITIVE DEFECT; DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INCONTINENCE; MORTALITY; ORTHOSTATIC HYPOTENSION; PARKINSONISM; REVIEW; SEIZURE; SIDE EFFECT; SURVIVAL; WEIGHT GAIN; PSYCHOLOGICAL ASPECT; RESTLESSNESS;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; ANXIETY; HUMANS; PSYCHOMOTOR AGITATION;

EID: 33745060775     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.5.705     Document Type: Review

References (41)

1. Ballard CG, Margallo-Lana M, Fossey J et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J. Clin. Psychiatry 62, 631-636 (2001).
2. Lyketsos CG, Steinebrg M, Tschanz JT. Mental and behavioural disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry 157, 708-714 (2000). One of the most important studies in the field.
3. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioural changes in Alzheimer's disease. Neurology 46, 130-135 (1996). First study on the general problem of behavioral alterations.
4. O'Donnell BF, Drachmen DA, Barnes HJ, Petersen KE, Swearer JM, Lew RA. Incontinence and troublesome behaviours predict institutionalization in dementia. J. Geriatr. Psych. Neurol. 5, 45-52 (1992).
5. Kaufer D. Treatment of behavioral symptoms in Alzheimer's disease. Am. Acad. Neurol. 35(9), 846-850 (2000).
6. Mintzer JE, Brawman-Mintzer O, Mirski D, Barkin K. Anxiety in the behavioral and psychological symptoms of dementia (BPSD). Int. Psychogeriatrics 12(Suppl.1), 139-142 (2000).
7. Feifel D. Psychopharmacology in the acute setting: review and proposed guidelines. Psychiatric Times XVIII(5) (2001).
8. Folstein MF, Bylsma FW. Noncognitive symptoms of Alzheimer disease. In: Alzheimer Disease, 2nd Edition. Terry RD, Katzmann R, Bick L, Sisodia SS (Eds), Lippincott Williams & Wilkins, PA, USA, 25-37 (1999). Very well written study on the topic.
9. Small GW, Rabins PV, Barry PP et al. Diagnosis and treatment of Alzheimer disease and related disorder. Consensus statement of the American Geriatric Association for Geriatric Psychiatry, the Alzheimer's Association and the American Geriatrics society. JAMA 278, 1363-1371 (1997).
10. Devanand DP, Marder K, Michaels KS et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychoses and disruptive behaviors in Alzheimer's Disease. Am. J. Psychiatry 155, 1512-1520 (1998).
11. De Deyn PP, Rabheru K, Rasmussen A et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53, 946-955 (1999).
12. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, double-blind trial. J. Clin. Psychiatry 60, 107-115 (1999).
13. McManus DQ, Arvanitis LA, Kowalcyk BB and the Seroquel Trial 48 Study Group. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J. Clin. Psychiatry 60, 292-298 (1999).
14. Street J, Clark S, Gannon KS et al. for the HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch. Gen. Psychiatry 57, 968-976 (2000).
15. Tariot PN, Ryan M, Porsteinsson AP, Loy R, Schneider LS. Pharmacologic therapy for behavioral symptoms of Alzheimer's disease. Clin. Geriatr. Med. 17, 359-376 (2001).
16. Aarsland D, Larsen JP, Cummings JL. Mortality and hallucination in Parkinson's disease: a four-year longitudinal study. J. Neuropsych. Clin. Neurosci. 9, 642 (1997).
17. Stern RG, Duffelmeyer ME, Zemishlani Z, Davidson M. The use of benzodiazepines in the management of behavioral symptoms in dementia patients. Psychiatr. Clin. North Am. 14, 375-384 (1991).
18. Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology 48(Suppl. 6), S17-S24 (1997). One of the most complete reviews on the pharmacology of the behavioral alterations.
19. Coccaro EF, Kramer E, Zemishlany Z et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am. J. Psychiatry 147, 1640-1645 (1990).
20. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J. Am. Geriatr. Soc. 38, 553-583 (1990).
21. Terry RD, Katzman R, Bick KL, Sisodia SS. Alzheimer Disease. Lippincott Williams and Wilkins, PA, USA (2000).
22. Devanand D, Sackeim H, Brown R, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch. Neurol. 46, 854-857 (1989).
23. Wood S, Cummings JL, Hsu MA et al. The use of the neuro-psychiatric inventory in nursing home residents. Characterization and measurement. Am. J. Geriatr. Psychiatry 8, 75-83 (2000).
24. Motsinger CD, Perron GA, Lacy TJ. Use of atypical antipsychotic drugs in patients with dementia. Am. Fam. Physician 67(11), 2335-2340 (2003).
25. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Expert Consensus Panel for using antipsychotic drugs in older patients. Using antipsychotic agents in older patients. J. Clin. Psychiatry 65(Suppl. 2), 5-99 (2004). Excellent review of the topic with a first attempt at a modern guideline.
26. Brodaty H, Ames D, Snowdon J et al. A randomized placebo-controlled trial of risperidone in the treatment of aggression, agitation and psychosis of dementia. J. Clin. Psychiatry 64(2), 134-143 (2003).
27. Meehan K, Wang H, David S et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 26, 494-504 (2002).
28. Lee PE, Gill SS, Freedman M, Bronksill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia: systematic review. Br. Med. J. 329(7457), 75 (2004).
29. Martin H, Slyk MP, Deymann S, Cornacchione MJ. Safety profile assessment of risperidone and olanzapin in long term care patients with dementia. J. Am. Med. Dir. Assoc. 4(4), 183-188 (2003).
30. Hwang JP, Yang CH, Lee TW, Tsai SJ. The efficacy and safety of olanzapine for the treatment of geriatric psycosis. J. Clin. Psychopharmacol. 23(2), 113-118 (2003).
31. Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilites. J. Clin. Psychiatry 64(6), 726-730 (2003).
32. Schatz RA. Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. Ann. Pharamacother. 37(9), 1321-1324 (2003).
33. Cummings JL. Neuropsychiatric symptoms and their treatments in patients with moderate to severe dementia. AAN, CA, USA, 3DS. 1-11 (2004).
34. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am. J. Psychiatry 161(6), 1113-1135 (2004).
35. Gill SS, Rochon PA, Herrmann N et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. Br. Med. J. 330, 7445-7489 (2005).
36. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294(15), 1934-1943 (2005).
37. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Canadian Medical Association journal 170(9), 1395 (2004).
38. De Deyn PP, Carrasco MM, Deberdt W et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 19(2), 115-126 (2004).
39. Hermann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am. J. Psychiatry 161, 1113-1115 (2004).
40. Mowat D. CSM warning on atypical psychotics and stroke may be detrimental for dementia. Br. Med. J. 328, 1262 (2004).
41. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G.Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study. J. Neurol. 252(10), 1186-1193 (2005).